Updated: 07 Jan 2001
1 Tbl. enth.: Lachesis D12 10 mg, Cimicifuga D5 10 mg, Sepia D5 10 mg, Lilium tigrinum D5 10 mg.
IL-17A in Psoriasis is intended for healthcare professionals involved in the treatment and management of patients with psoriasis. This resource has been developed primarily to discuss the role of the IL-17 pathway in the pathogenesis of psoriasis and the therapeutic potential of treatments directed towards IL-17A. Users can expect to find sections containing expert videos, clinical slide decks, congress highlights, key publications and links to useful resources.
This resource has been developed in collaboration with Novartis Pharma AG.
The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’.
See disease awareness facts and stats, information on sebelipase alfa (the first and only licensed treatment for LAL-D) and resources section, including expert video channel…